Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example

BACKGROUND: The US FDA and the EMA have approved seven agents for the treatment of renal cell carcinoma, primarily based on differences in progression-free survival (PFS). Because PFS is an arbitrary endpoint we hypothesized that an analysis would demonstrate the growth rate of tumors remained const...

Descripción completa

Detalles Bibliográficos
Autores principales: Burotto, Mauricio, Wilkerson, Julia, Stein, Wilfred, Motzer, Robert, Bates, Susan, Fojo, Tito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010463/
https://www.ncbi.nlm.nih.gov/pubmed/24796484
http://dx.doi.org/10.1371/journal.pone.0096316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010463/
https://www.ncbi.nlm.nih.gov/pubmed/24796484
http://dx.doi.org/10.1371/journal.pone.0096316

Ejemplares similares